JIN YANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,410 KRW | 0.00% |
|
+0.19% | -12.60% |
| Apr. 09 | Jin Yang Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till April 9, 2025. | CI |
| 2023 | Jin Yang Pharmaceutical Co. Ltd.'s Equity Buyback Plan Extended till December 22, 2024. | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 42,027 | 49,181 | 78,242 | 78,689 | 70,257 | 66,805 |
| Enterprise Value (EV) 1 | 50,813 | 52,947 | 79,058 | 83,827 | 79,745 | 71,147 |
| P/E ratio | 45 x | 29.9 x | 21.3 x | 8.35 x | 6.61 x | 5.27 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.9 x | 1.04 x | 1.6 x | 1.25 x | 0.92 x | 0.71 x |
| EV / Revenue | 1.08 x | 1.12 x | 1.62 x | 1.33 x | 1.05 x | 0.76 x |
| EV / EBITDA | 14.2 x | 27.9 x | 14 x | 9.19 x | 5.94 x | 6.06 x |
| EV / FCF | 36.4 x | 11.3 x | 37.2 x | -19.5 x | -42.1 x | 25.4 x |
| FCF Yield | 2.75% | 8.87% | 2.69% | -5.12% | -2.38% | 3.94% |
| Price to Book | 1 x | 1.13 x | 1.69 x | 1.2 x | 0.91 x | 0.74 x |
| Nbr of stocks (in thousands) | 11,177 | 11,177 | 11,177 | 11,177 | 10,776 | 10,792 |
| Reference price 2 | 3,760 | 4,400 | 7,000 | 7,040 | 6,520 | 6,190 |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 46,863 | 47,351 | 48,810 | 62,839 | 76,264 | 94,111 |
| EBITDA 1 | 3,574 | 1,898 | 5,651 | 9,117 | 13,429 | 11,740 |
| EBIT 1 | 1,465 | -216.3 | 3,545 | 6,964 | 11,138 | 9,085 |
| Operating Margin | 3.13% | -0.46% | 7.26% | 11.08% | 14.61% | 9.65% |
| Earnings before Tax (EBT) 1 | 1,901 | 2,070 | 4,544 | 12,132 | 14,535 | 12,583 |
| Net income 1 | 933.2 | 1,647 | 3,677 | 9,538 | 12,308 | 12,659 |
| Net margin | 1.99% | 3.48% | 7.53% | 15.18% | 16.14% | 13.45% |
| EPS 2 | 83.49 | 147.3 | 328.9 | 843.0 | 986.0 | 1,175 |
| Free Cash Flow 1 | 1,396 | 4,695 | 2,127 | -4,291 | -1,894 | 2,805 |
| FCF margin | 2.98% | 9.92% | 4.36% | -6.83% | -2.48% | 2.98% |
| FCF Conversion (EBITDA) | 39.07% | 247.32% | 37.63% | - | - | 23.9% |
| FCF Conversion (Net income) | 149.62% | 285.11% | 57.84% | - | - | 22.16% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 8,786 | 3,766 | 816 | 5,138 | 9,488 | 4,341 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.459 x | 1.984 x | 0.1444 x | 0.5635 x | 0.7065 x | 0.3698 x |
| Free Cash Flow 1 | 1,396 | 4,695 | 2,127 | -4,291 | -1,894 | 2,805 |
| ROE (net income / shareholders' equity) | 2.21% | 3.84% | 8.17% | 16.8% | 17.2% | 15.1% |
| ROA (Net income/ Total Assets) | 1.27% | -0.2% | 3.25% | 5.12% | 6.54% | 4.85% |
| Assets 1 | 73,309 | -842,812 | 113,123 | 186,373 | 188,251 | 261,240 |
| Book Value Per Share 2 | 3,762 | 3,907 | 4,143 | 5,844 | 7,199 | 8,319 |
| Cash Flow per Share 2 | 7.730 | 153.0 | 463.0 | 1,049 | 69.90 | 475.0 |
| Capex 1 | 327 | 737 | 1,363 | 2,516 | 3,218 | 682 |
| Capex / Sales | 0.7% | 1.56% | 2.79% | 4% | 4.22% | 0.72% |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -12.60% | 42.42M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A007370 Stock
- Financials Jin Yang Pharmaceutical Co., Ltd.
